Testing Whether Glucagon Solutions Affect the Glucose Levels in the Fat Tissue of Diabetic Patients.

Active, not recruiting

• Conditions: Diabetes Mellitus type 1; MedDRA version: 17.0Level: LLTClassification code 10012608Term: Diabetes mellitus insulin-dependentSystem Organ Class: 100000004861; Therapeutic area: Diseases [C] - Hormonal diseases [C19]

• Registration Number: EUCTR2014-002341-22-AT
• Lead Sponsor: Medizinische Universität Graz; Universitätsklinik für InnereMedizin; Abteilung für Endokrinologie und Stoffwechsel

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2014-06-11
• Last Update Posted: 22 December 2015

Recruitment & Eligibility

• Status: Not Recruiting
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

- 18 to 64 years of age, both inclusive
- Type 1 diabetes treated with CSII or MDI
- HbA1C < 10%
- BMI between 20 and 30 kg/m2
- Signed informed consent before any study-related activities
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 10
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range 0

Exclusion Criteria

- Severe acute diseases
- Clinically overt diabetic complications
- Mental incapacity, unwillingness or language barriers precluding adequate understanding or co-operation
- Taking of any vasoactive substances or anticoagulation medication
- Diseases of the skin which could interfere with application of catheters as judged by the investigator
- Uncontrolled hypertension
- Use of a medication that significantly impacts glucose metabolism (e.g. oral or topical steroids) except in the case of a stable state with a minimum duration of at least three months preceding the study as well as under the condition that the state remain stable for the duration of the study
- No superficial veins for catheter insertion as judged by the investigator
- Pregnancy, breastfeeding, intention of becoming pregnant or not using adequate contraception.
- Any disease or condition which the investigator or treating physician feels would interfere with the trial or the safety of the subject
- Concurrent participation in another study

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified